Learn to build successful partnerships between #pharma and #digitalhealth companies https://lnkd.in/edgvx7id Brought to you by Ypsomed AG #patientcare #pharmaceuticals #Ypsomed
FirstWord Pharma
Pharmaceutical Manufacturing
London, London 24,321 followers
Where people who know first, go first.
About us
FirstWord Pharma is a trusted news and analysis service that keeps pharmaceutical professionals up-to-date with the latest industry news and intelligence from across the globe. Fast and reliable news delivery of the latest developments in the pharma industry, with related analyses, physician polls and executive interviews to provide deeper insights. Never miss the critical developments shaping the industry with news and analysis delivered to your inbox daily. Register for our free daily industry newsletter at https://www.firstwordpharma.com/register FirstWord Pharma+, our personalized premium news service, allows you to monitor and track specific compounds/products, companies, medical conditions, and international medical meetings, as well as markets and regulatory bodies, to provide you with the most relevant news and intelligence vital to your needs. Out of the main providers in this field, our clients consider FirstWord content deeper and more insightful than others, and our news service the fastest on the market. That's what sets us apart. Our platform is where people who know first, go first.
- Website
-
https://firstwordpharma.com/
External link for FirstWord Pharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- London, London
- Founded
- 2005
Updates
-
Is Bristol Myers Squibb's Cobenfy poised to revolutionise the treatment of #schizophrenia? FirstWord is speaking with a leading KOL to find out. Learn more here: https://lnkd.in/dbP7YTMu #BMS #clinicalresearch #medicalaffairs #pharmaceuticals #productapprovals #regulatoryaffairs
KOL Views Preview: Is BMS’s Cobenfy poised to revolutionise the treatment of schizophrenia?
-
GSK reported that its respiratory syncytial virus (RSV) vaccine Arexvy demonstrated sustained efficacy over three full #RSV seasons. https://lnkd.in/ev2eP6dv #clinicalresearch #clinicaltrials #drugdevelopment #GSK #immunization #pharmaceuticals #respiratory #vaccines
GSK touts three-season staying power for Arexvy in latest RSV data
-
Merck is turning to Mestag Therapeutics and its RAFT platform in an effort to identify new targets for #inflammatory diseases, marking the second big #pharma company to join forces with the UK #biotech. https://lnkd.in/erDCUzw4 #biotechnology #immunology #licensing #Merck #MestagTherapeutics #pharmaceuticals
Merck & Co. in tie up with Mestag on inflammatory disease targets
-
Sage Therapeutics is ending development of dalzanemdor (SAGE-718) in #Alzheimersdisease after the NMDA receptor positive allosteric modulator failed to meet the primary endpoint of a mid-stage study. https://lnkd.in/dsZfBnGZ #Alzheimers #biotechnology #clinicalresearch #drugdevelopment #pharmaceuticals #SageTherapeutics
Dementia miss means Sage's hopes for dalzanemdor rest on Huntington's readout
-
Astellas Pharma is continuing to expand its #genetherapy pipeline via external deals, this time with an asset from AviadoBio for patients with frontotemporal #dementia with progranulin mutations (FTD-GRN). https://lnkd.in/dG24bJPC #Astellas #AviadoBio #biotechnology #licensing #orphandrugs #pharmaceuticals
Astellas continues gene therapy push with $2B deal for AviadoBio's frontotemporal dementia asset
-
Johnson & Johnson announced that it is discontinuing a Phase III study of its drug-device combination TAR-200 to treat patients with muscle-invasive #bladdercancer (MIBC) after failing to demonstrate superiority over chemoradiation. https://lnkd.in/d7Gr5ixK #cancer #clinicalresearch #clinicaltrials #drugdevelopment #JnJ #oncology #pharmaceuticals
J&J's bladder cancer long shot misses mark versus chemoradiation
-
Boehringer Ingelheim has made good on its promise of rapidly advancing survodutide into Phase III development for metabolic dysfunction-associated steatohepatitis (MASH), kicking off a pair of pivotal studies for the glucagon/GLP-1 receptor dual agonist. https://lnkd.in/dyjdf-CV #BoehringerIngelheim #clinicalresearch #clinicaltrials #drugdevelopment #MASH #pharmaceuticals #regulatoryaffairs
Boehringer kicks off late-stage MASH studies of survodutide
-
Liquidia Corporation's stock rebounded after the US Supreme Court threw out an appeal from United Therapeutics Corporation seeking to overturn an earlier ruling regarding the validity of its patents for #hypertension treatment Tyvaso DPI (treprostinil). https://lnkd.in/dhf2ANTE #biotechnology #Liquidia #lungdisease #pharmaceuticals #UnitedTherapeutics
Liquidia shares jump after US Supreme Court rejects competitor's patents
-
Black Diamond Therapeutics announced that two members of its leadership team have been let go amid a wider restructuring designed to carry its lead programme BDTX-1535 through to a Phase II readout in the first quarter of 2025. https://lnkd.in/dnFMqCkx #biotechnology #BlackDiamondTherapeutics #pharmaceuticals
Black Diamond culls C-suite, downgrades cancer asset in pipeline reprioritisation